Request that the FDA Immediate Administrative and Enforcement Action Against 503B Outsourcing Facilities Distributing Adulterated and Misbranded Ophthalmic Bevacizumab Products
🏛 Food and Drug Administration (FDA)FDA-2026-P-2257
Documents
2
Total comments
2
all analyzed
Comment status
Closed
Last activity
—
In this docket
Documents
Rules, notices, and supporting material — the primary rule pinned first.
📄 Primary document
- Other· Mar 4, 2026No comment period💬 2